Gastric Cancer Branch, Research Institute and Hospital, National Cancer Center, Goyang, Republic of Korea.
Department of Surgery, Philippine General Hospital, University of the Philippines, Manila, Philippines.
BMC Cancer. 2018 Jan 12;18(1):73. doi: 10.1186/s12885-017-3872-6.
Greater lymph node retrieval in gastric cancer improves staging accuracy and may improve survival from increased clearance of nodal micrometastasis. This retrospective cohort study investigated if more lymph nodes removed in gastric cancer increases survival and if such effect is stage-specific due to differential risks of nodal micrometastasis and systemic disease.
The prospectively collected database of curatively resected gastric cancer patients in National Cancer Center, South Korea between 2000 and 2009 was reviewed. Disease-free survival (DFS) and overall survival (OS) for all patients and for each stage according to number of lymph nodes examined (1-30, 31-45, > 45) were analyzed.
Of 4049 patients, 96.6% and 98.4% underwent D2 (perigastric and extragastric) lymphadenectomy and had ≥ 15 lymph nodes examined. Mean number of nodes examined was 43. Five-year OS & DFS rates were 83.3% and 80.7%. Patients with > 45 nodes examined had significantly lower DFS (p = 0.002) and OS (p = 0.007) compared to those with 1-30 and 31-45 nodes. However, proportion of patients with > 45 nodes examined increased with stage (p = 0.0005). Per stage, there was no significant difference in DFS and OS according to number of nodes examined except for stage IIIA favoring more nodes (p = 0.018 and p = 0.044, respectively). Similar trend was seen in stage IIB. Number of examined nodes positively correlated with number of pathologic nodes for all patients (r = 0.144, p < .001) but not for stage IIB and IIIA. Number of nodes examined was a significant survival predictor in stage IIIA.
Greater lymph node harvest showed improved survival in intermediate-stage gastric cancer.
胃癌中更多的淋巴结采集可提高分期准确性,并可能通过清除更多淋巴结微转移来提高生存。本回顾性队列研究旨在探讨胃癌中更多淋巴结切除是否能提高生存率,以及这种效果是否因淋巴结微转移和全身性疾病的不同风险而具有分期特异性。
回顾性分析韩国国家癌症中心 2000 年至 2009 年期间接受根治性切除的胃癌患者的前瞻性数据库。分析所有患者及根据检查淋巴结数量(1-30、31-45、>45)的每个分期的无病生存率(DFS)和总生存率(OS)。
在 4049 例患者中,96.6%和 98.4%行 D2(胃周和胃外)淋巴结清扫术,且有≥15 个淋巴结被检查。平均检查的淋巴结数量为 43 个。5 年 OS 和 DFS 率分别为 83.3%和 80.7%。与 1-30 个和 31-45 个淋巴结相比,>45 个淋巴结检查的患者 DFS(p=0.002)和 OS(p=0.007)显著降低。然而,随着分期的增加,检查>45 个淋巴结的患者比例增加(p=0.0005)。各分期中,DFS 和 OS 与淋巴结检查数量无显著差异,除 IIIA 期(DFS:p=0.018;OS:p=0.044)外。IIIB 期也有类似趋势。所有患者的检查淋巴结数量与病理淋巴结数量呈正相关(r=0.144,p<0.001),但 IIIB 期和 IIIA 期除外。检查的淋巴结数量是 IIIA 期的一个显著生存预测因子。
在中晚期胃癌中,更多的淋巴结采集显示出更好的生存。